Induction of a host of anti-apoptotic genes by GST-PTR1 suggested the possibility that HAPLN1-PTR1 might induce resistance of MM cells to not only bortezomib but also other clinically employed FDA-approved drugs. The gene discussed is HAPLN1; the disease is Miyoshi myopathy.